feinstein, northwell
Northwell Health's Feinstein Institutes for Medical Research is beginning three studies alongside Sanofi, Gilead Sciences and Regeneron Pharmaceuticals. These studies will test possible treatments for moderate and severe cases of COVID-19. (Photo via Northwell Health)

Northwell Health’s Feinstein Institutes Teams Up with Sanofi, Regeneron Pharmaceuticals, Gilead Sciences to Test COVID-19 Treatments

The research arm of Northwell Health (No. 2 on DiversityInc’s 2019 Top Hospitals & Health Systems), the Feinstein Institutes for Medical Research, is partnering with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi (No. 31 on DiversityInc’s 2019 Top 50 Companies for Diversity) to identify treatments for people hospitalized with moderate to severe cases of the novel coronavirus (COVID-19).

The Feinstein Institutes announced last week the enrollment of three clinical trials aimed at finding an effective treatment for those diagnosed with the coronavirus. Due to the urgency of the issue, there has been a nationwide push for expedited Food and Drug Administration (FDA) approvals of experimental COVID-19 therapies. However, Northwell Health and the Feinstein Institutes announced the trials would continue through the typical, lengthier process to ensure accuracy.

Two of the trials, which will be conducted with Gilead, will involve the drug remdesivir. Remdesivir is an antiviral drug that is designed to reduce the length and intensity of a COVID-19 infection. Northwell Health said the drug had shown promise in working against similar viruses like MERS and SARS in test tubes and animal models. The first trial has room for 400 subjects with severe cases of COVID-19 worldwide. Researchers will administer the drug intravenously in two different durations and measure patients’ bodies’ responses. Feinstein Institutes’ Marcia Epstein, MD, an infectious disease expert, will lead this study.

The other Gilead remdesivir trial will assess two different durations of treatment with the drug and compare it to the current treatment methods in up to 600 patients with moderate cases of COVID-19. Researchers will also look at improvement of symptoms and time of discharge. Prashant Malhotra, MD, will lead this study. Malhotra is an assistant professor of the Institute of Health Innovations & Outcomes Research at Feinstein Institutes and is an infectious disease expert.

In the third study, Feinstein will collaborate with Regeneron and Sanofi. The trial will look at approximately 400 severe or critical cases of COVID-19 in hospitals across the U.S. This trial will study the efficacy of a human antibody called sarilumab that may help prevent complications connected to severe pneumonia in COVID-19 patients. This study adds to a preliminary Chinese trial that found the use of the antibody helped reduce fever in all patients.

China has approved its use to treat patients with severe or critical cases. Negin Hajizadeh, MD, an assistant professor in the Institute of Health Innovations & Outcomes Research and a pulmonary critical care doctor will be leading this study.

To read more about these studies and Northwell’s plans to combat COVID-19, visit northwell.edu.

Latest News

Biden Stands by His Commitment to LGBTQ rights; Cost of Racism in the U.S. Tops $16 Trillion; Black and Latinx Continue to Die from COVID-19 at Nearly Twice the Rate of Whites; and More

Biden reaffirms commitment to LGBTQ rights; promises to pass Equality Act. Democratic presidential nominee Joe Biden doubled down on his promises to the LGBTQ community while speaking at a presidential town hall for the Human Rights Campaign Foundation on Sept. 24. “You deserve a partner in the White House to…

degeneres, work, show

Leadership Lessons to be Gleaned from Ellen DeGeneres’ Toxic Workplace Scandal

Ellen DeGeneres began her daytime talk show’s 18th season with an apology after a summer of allegations against her that claimed her show promoted a toxic work environment rife with racism, sexual misconduct and other mistreatment. In August 2020, three senior producers — executive producers Ed Glavin and Kevin Leman…

COVID entrepreneur

Explosive New Growth in Small Businesses Due to COVID-19; America’s Police Force is Not Becoming More Diverse Despite BLM Movement; the Best and Worst Performing States in the 2020 Census; and More

Even with incredible nationwide unemployment rates, the creation of new small and diverse businesses has exploded due to COVID-19. Finally some news coming out of our pandemic: The Philadelphia Tribune reports that as bars and restaurants closed and stay-at-home orders were put into place earlier in 2020 to help fight…

Justice for Breonna not served; The essential rule of politics; Teen serves two months in jail for not doing homework; and More

Justice for Breonna not served as grand jury indicted officer who shot her with wanton endangerment — but not murder. “Outrageous and offensive.” Those were  by attorney to the family, Ben Crump to describe the grand jury’s decision in the March 13 fatal police shooting of 26-year-old Breonna Taylor. While…

IBM, EEOC, age

EEOC Unearths Years of Intentional Age Discrimination within IBM

After a long investigation, the Equal Employment Opportunity Commission (EEOC) has revealed that IBM leaders had directed managers to replace older workers with younger ones. Between 2013 and 2018, nearly 86% of those considered for layoffs within the organization were older employees over the age of 40. The investigation showed…

Breathe March in Globe Park, New York, USA - 12 Sep 2020

Cities under attack from the Justice Department; Louisville bracing for the Breonna Taylor murder charge; Twitter reveals its racist side; and More

Justice department attacks three U.S. cities, declaring them anarchist zones — despite most of the protests that took place in each city being peaceful marches in support of the Black Lives Matter movement. In a move designed to pull federal funding from New York City, Seattle and Portland, OR, the…

ginsburg, supreme, court

The Lasting Legacy of Supreme Court Justice Ruth Bader Ginsburg — Plus the Four Biggest Issues Currently at Stake Following Her Death

Supreme Court Justice Ruth Bader Ginsburg, who served on the nation’s highest court for 27 years, passed away Friday, Sept. 18 at the age 87. “As the second woman ever to sit on the highest court in the land, she was a warrior for gender equality — someone who believed…